Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

What Role do Inflammatory Cytokines Play in Creating T Cell Exhaustion in Cancer?

By Mary Ann Liebert, Inc./Genetic Engineering News | August 3, 2018

A better understanding of the role secreted inflammatory cytokines play in the tumor microenvironment that results in the differentiation of effector T cells into exhausted T cells points to possible approaches to improve the antitumor activity of T cells and to intervene in T cell exhaustion. A new article exploring the expression patterns of inflammatory cytokines in tumor tissues and the blood of cancer patients and seeking to understand how exhausted T cells lose their antitumor properties is published in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers . The article is available free on the Cancer Biotherapy and Radiopharmaceuticals website through September 3, 2018.

In the review article, “The Role of Inflammatory Cytokines in Creating T Cell Exhaustion in Cancer,” Hedayatollah Shirzad and colleagues from Shahrekord University, Shahrekord, Iran report on multiple studies that illustrate a direct role for inflammatory cytokines in the creation of cell exhaustion through multiple pathways. The researchers recommend a greater focus on efforts to reprogram exhausted T cells in the early stages and alternatively, therapeutic interventions such as anti-inflammation therapy.

“Clearly there is room and need for further understanding of the role and functional consequences of exhausted T cells as they relate to impacting on the immune system, how that interplays with outcomes in cancer therapies, and how advantages might be taken to improve existing therapeutic strategies,” says Cancer Biotherapy and RadiopharmaceuticalsEditor-in-Chief Martin W. Brechbiel, PhD.

About the Journal

Cancer Biotherapy and Radiopharmaceuticals ,” published 10 times per year in print and online, is the only peer-reviewed journal with a specific focus on cancer biotherapy, including monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapy. Led by Editor-in-Chief Martin W. Brechbiel, PhD, the Journalincludes extensive reporting on advancements in radioimmunotherapy and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. Tables of content and a sample issue can be viewed on the Cancer Biotherapy and Radiopharmaceuticals website.


Filed Under: Oncology

 

Related Articles Read More >

New treatment paradigms in oncology: Highlights from the ASCO 2025 annual meeting
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
As some biotechs cut, Genmab unveils striking new site near Princeton
OS Therapies announces favorable FDA feedback on external control arm strategy for osteosarcoma drug
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE